Krebs Biochemicals Q1 FY27 Unaudited Results Declared
Krebs Biochemicals reported Q1 FY27 un-audited results. Total income was ₹714.00 lakhs. Net loss after tax was ₹248.48 lakhs, compared to a loss of ₹233.96 lakhs in Q1 FY26. Basic and diluted EPS stood at ₹(1.15) for Q1 FY27.
The results show a net loss, which could impact investor confidence, but the scale of the loss and its comparison to previous periods warrant a medium impact assessment.
The company reported a net loss for the quarter, indicating a negative financial performance compared to the previous year's quarter.
Krebs Biochemicals and Industries Limited announced its un-audited financial results for the first quarter ended June 30, 2026. The results were approved in the Board Meeting held on August 6, 2026, and were published on August 7, 2026, in Business Standard (English) and Prajasakti (Telugu).
The company reported total income from operations of ₹714.00 lakhs for the quarter ended June 30, 2026. The net profit/(loss) from ordinary activities before tax, exceptional and/or extraordinary items was ₹(248.48) lakhs. The net profit/(loss) for the period after tax was also ₹(248.48) lakhs. Total comprehensive income for the period stood at ₹(248.48) lakhs.
For the corresponding quarter ended June 30, 2025, the total income from operations was ₹881.27 lakhs, with a net profit/(loss) after tax of ₹(233.96) lakhs. For the year ended March 31, 2026, the total income from operations was ₹2,575.79 lakhs and the net profit/(loss) after tax was ₹(1,693.31) lakhs.
Earnings per share (EPS) for the quarter ended June 30, 2026, both basic and diluted, were ₹(1.15). This compares to ₹(1.09) for the same period in the previous year and ₹(7.85) for the year ended March 31, 2026.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.